Free tool
FAERS Monitor: Yasmin
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021098 or its brand name (Yasmin, Drospirenone, Ethinyl Estradiol). Reports on generic versions are filed under their own applications.
Reports
24,602
Serious
21,826
89% of reports
Hospitalization
12,693
Death reported
428
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- pain8,959
- injury7,736
- pulmonary embolism5,825
- deep vein thrombosis5,609
- anxiety4,646
- emotional distress4,574
- cholecystitis chronic3,785
- cholelithiasis2,794
- gallbladder disorder2,760
- general physical health deterioration2,324
- abdominal pain1,739
- nausea1,652
- anhedonia1,554
- thrombosis1,419
- dyspnoea1,338
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 199 |
| 2005 | 284 |
| 2006 | 322 |
| 2007 | 329 |
| 2008 | 1,375 |
| 2009 | 705 |
| 2010 | 1,404 |
| 2011 | 6,766 |
| 2012 | 6,083 |
| 2013 | 3,245 |
| 2014 | 1,658 |
| 2015 | 489 |
| 2016 | 267 |
| 2017 | 163 |
| 2018 | 190 |
| 2019 | 188 |
| 2020 | 180 |
| 2021 | 127 |
| 2022 | 144 |
| 2023 | 164 |
| 2024 | 127 |
| 2025 | 99 |
| 2026 | 94 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,029,557 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| cholecystitis chronicSignal | 3,785 | 1108.4 | 1057.9 | 1,823,462 |
| gallbladder disorderSignal | 2,760 | 156.1 | 150.2 | 359,880 |
| injurySignal | 7,736 | 105.6 | 103.5 | 715,502 |
| deep vein thrombosisSignal | 5,609 | 80.7 | 78.7 | 404,427 |
| cholelithiasisSignal | 2,794 | 79.5 | 76.7 | 198,462 |
| pulmonary embolismSignal | 5,825 | 55.8 | 54.5 | 295,331 |
| anhedoniaSignal | 1,554 | 53.7 | 51.1 | 75,615 |
| emotional distressSignal | 4,574 | 33.5 | 32.6 | 139,669 |
| general physical health deteriorationSignal | 2,324 | 17.5 | 16.8 | 35,616 |
| thrombosisSignal | 1,419 | 15.3 | 14.6 | 18,730 |
| anxietySignal | 4,646 | 14.2 | 13.8 | 56,704 |
| painSignal | 8,959 | 12.6 | 12.4 | 97,454 |
| abdominal painSignal | 1,739 | 6.4 | 6.1 | 8,000 |
| dyspnoeaSignal | 1,338 | 2.0 | 1.9 | 709 |
| nausea | 1,652 | 1.8 | 1.7 | 592 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.